Payment overview · 2025
General Payments
$711.84
36 reported records · 13 companies
Healthcare provider profile · identity verified
William N Boulware, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, SC · NPI 1518930940
Verified facts
What the public records show
CMS Open Payments records show William N Boulware, MD received $711.84 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic, Rybelsus, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $258.42 | 36.3% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $95.02 | 13.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.78 | 11.6% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.64 | 9.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.01 | 7.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.32 | 5.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.72 | 3.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.91 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.52 | 2.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.41 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.34 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.81 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.94 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $711.84 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.19 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $95.02 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $82.78 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.62 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $64.64 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.62 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
50 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 70 |
| Omeprazole | Omeprazole | 263 | 52 |
| Gabapentin | Gabapentin | 257 | 50 |
| Eliquis | Apixaban | 240 | 36 |
| Furosemide | Furosemide | 238 | 47 |
| Trazodone Hcl | Trazodone Hcl | 222 | 52 |
| Ezetimibe | Ezetimibe | 207 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 36 |
| Irbesartan | Irbesartan | 170 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 36 |
| Allopurinol | Allopurinol | 151 | 30 |
| Donepezil Hcl | Donepezil Hcl | 145 | 25 |
| Losartan Potassium | Losartan Potassium | 144 | 26 |
| Famotidine | Famotidine | 137 | 30 |
| Potassium Chloride | Potassium Chloride | 137 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 30 |
| Montelukast Sodium | Montelukast Sodium | 127 | 32 |
| Tramadol Hcl | Tramadol Hcl | 126 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 28 |
| Alprazolam | Alprazolam | 122 | 21 |
| Jardiance | Empagliflozin | 119 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 26 |
| Spironolactone | Spironolactone | 110 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 32 |
| Metformin Hcl Er | Metformin Hcl | 109 | 24 |
| Bupropion Xl | Bupropion Hcl | 107 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 17 |
| Meloxicam | Meloxicam | 104 | 26 |
| Prednisone | Prednisone | 96 | 62 |
| Carvedilol | Carvedilol | 94 | 23 |
| Celecoxib | Celecoxib | 92 | 17 |
| Glipizide Er | Glipizide | 92 | 17 |
| Pregabalin | Pregabalin | 92 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 21 |
| Lisinopril | Lisinopril | 89 | 21 |
| Cefdinir | Cefdinir | 87 | 58 |
| Synthroid | Levothyroxine Sodium | 87 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 65 |
| Xarelto | Rivaroxaban | 82 | 11 |
| Ondansetron Odt | Ondansetron | 78 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | suppressed |
| Rybelsus | Semaglutide | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Simvastatin | Simvastatin | 66 | 12 |
| Ozempic | Semaglutide | 64 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 42 |
| Methylprednisolone | Methylprednisolone | 58 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 57 | 13 |
| Lorazepam | Lorazepam | 57 | 15 |
| Mirtazapine | Mirtazapine | 57 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 12 |
| Metformin Hcl | Metformin Hcl | 56 | 14 |
| Finasteride | Finasteride | 54 | 12 |
| Sucralfate | Sucralfate | 54 | 18 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 53 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | suppressed |
| Temazepam | Temazepam | 51 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 50 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 48 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | suppressed |
| Nitroglycerin | Nitroglycerin | 47 | 21 |
| Ramipril | Ramipril | 46 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 42 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 19 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Sotalol | Sotalol Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 18 |
| Linzess | Linaclotide | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Nystatin | Nystatin | 34 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Testosterone | Testosterone | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 12 |
| Dexamethasone | Dexamethasone | 32 | 19 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Rabeprazole Sodium | Rabeprazole Sodium | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Valsartan | Valsartan | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 27 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Dofetilide | Dofetilide | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Estradiol | Estradiol | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Felodipine Er | Felodipine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lipitor | Atorvastatin Calcium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $711.84 · 36 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, NEXLETOL, NUPLAZID, OTEZLA, Ozempic, PREVNAR 20, RELISTOR, REPATHA, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error